TherapeuticsMD, Inc. (TXMD)

NMS – Real vaqt narxi. Valyuta: USD

2.11

+0.08 (3.94%)

Yopilishda: Jun 26, 2026, 4:00 PM EDT

2.15

+0.04 (1.90%)

Bozordan keyin: Jun 26, 2026, 7:06 PM EDT

12.05.2026

TherapeuticsMD Announces First Quarter 2026 Financial Results

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the three months ended March 31, 2026. First Quarter 2026 Financial Results Net Income (Loss) from Continuing Operations Net income from continuing operations totaled $103 thousand, compared to a net loss of $636 thousand for the first quarter of 2025. License Revenues from Continuing Operations T.

30.03.2026

TherapeuticsMD Announces Full Year 2025 Financial Results

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the full year ended December 31, 2025. Full Year 2025 Financial Results Net Loss from Continuing Operations Net loss from continuing operations was $(0.7) million, or $(0.06) per basic and diluted common share, an improvement of $1.7 million, compared to net loss from continuing operations of $(2.

12.11.2025

TherapeuticsMD Announces Third Quarter 2025 Financial Results

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the three months ended September 30, 2025. Third Quarter 2025 Financial Results Net Income (Loss) from Continuing Operations Net income from continuing operations was $50 thousand, or $0.00 per basic and diluted common share, compared to a net loss of $567 thousand, or $0.05 per basic and diluted.

Videolar

No Data

There is no data to display

Press-relizlar

12.05.2026

TherapeuticsMD Announces First Quarter 2026 Financial Results

30.03.2026

TherapeuticsMD Announces Full Year 2025 Financial Results

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the full year ended December 31, 2025. Full Year 2025 Financial Results Net Loss from Continuing Operations Net loss from continuing operations was $(0.7) million, or $(0.06) per basic and diluted common share, an improvement of $1.7 million, compared to net loss from continuing operations of $(2.

12.11.2025

TherapeuticsMD Announces Third Quarter 2025 Financial Results

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the three months ended September 30, 2025. Third Quarter 2025 Financial Results Net Income (Loss) from Continuing Operations Net income from continuing operations was $50 thousand, or $0.00 per basic and diluted common share, compared to a net loss of $567 thousand, or $0.05 per basic and diluted.

TherapeuticsMD, Inc. (TXMD)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

TherapeuticsMD, Inc. (TXMD)

TherapeuticsMD Announces First Quarter 2026 Financial Results

TherapeuticsMD Announces Full Year 2025 Financial Results

TherapeuticsMD Announces Third Quarter 2025 Financial Results

Videolar

No Data

Press-relizlar

TherapeuticsMD Announces First Quarter 2026 Financial Results

TherapeuticsMD Announces Full Year 2025 Financial Results

TherapeuticsMD Announces Third Quarter 2025 Financial Results

TherapeuticsMD Announces First Quarter 2026 Financial Results

TherapeuticsMD Announces Full Year 2025 Financial Results

TherapeuticsMD Announces Third Quarter 2025 Financial Results

Videolar

No Data

Press-relizlar

TherapeuticsMD Announces First Quarter 2026 Financial Results

TherapeuticsMD Announces Full Year 2025 Financial Results

TherapeuticsMD Announces Third Quarter 2025 Financial Results

Search stocks

TherapeuticsMD, Inc. (TXMD)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

TherapeuticsMD, Inc. (TXMD)

TherapeuticsMD Announces First Quarter 2026 Financial Results

TherapeuticsMD Announces Full Year 2025 Financial Results

TherapeuticsMD Announces Third Quarter 2025 Financial Results

Videolar

No Data

Press-relizlar

TherapeuticsMD Announces First Quarter 2026 Financial Results

TherapeuticsMD Announces Full Year 2025 Financial Results

TherapeuticsMD Announces Third Quarter 2025 Financial Results

TherapeuticsMD Announces First Quarter 2026 Financial Results

TherapeuticsMD Announces Full Year 2025 Financial Results

TherapeuticsMD Announces Third Quarter 2025 Financial Results

Videolar

No Data

Press-relizlar

TherapeuticsMD Announces First Quarter 2026 Financial Results

TherapeuticsMD Announces Full Year 2025 Financial Results

TherapeuticsMD Announces Third Quarter 2025 Financial Results